Lantern Pharma (NASDAQ: LTRN) announced the commercial launch of withZeta.ai, its multi-agentic AI co-scientist platform for rare cancer drug discovery, with subscriptions now available across academic and commercial tiers, creating a new non-dilutive revenue stream for the company. The platform, built from Lantern’s RADR (R) oncology-focused AI technologies, will be showcased at a private investor event at Nasdaq MarketSite in New York on April 16, 2026, and demonstrated publicly at the AACR Annual Meeting in San Diego from April 17–22, highlighting its capabilities in accelerating molecular design, clinical development and biomedical research.
To view the full press release, visit https://ibn.fm/INjHb
About Lantern Pharma Inc.
Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR(R) platform to transform the development of cancer therapies. Lantern’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. withZeta.ai , Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
About withZeta.ai
withZeta.ai is redefining how rare cancer research, discovery, drug development, and clinical trial design gets done. Knowledge work in oncology is migrating to AI co-scientists — autonomous systems that investigate, reason, and synthesize across the full breadth of scientific evidence. withZeta.ai is that co-scientist: purpose-built for the biology, economics, and urgency of rare cancer drug development, and accessible to any researcher, anywhere. Built by Lantern Pharma (Nasdaq: LTRN). Learn more and subscribe at withzeta.ai.
NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN
About AINewsWire
AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.
AINW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from AINewsWire, text “AI” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit www.AINewsWire.com
Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer
AINewsWire
Austin, Texas
www.AINewsWire.com
512.354.7000 Office
Editor@AINewsWire.com
AINewsWire is powered by IBN
